PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-29.38%
Cash & equivalents declining -29.38% while AVXL's grows 237.78%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Below half of AVXL's 237.78%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-29.50%
Below half of AVXL's 614.58%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Below half of AVXL's 614.58%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-13.35%
Less than half of AVXL's 104633.80%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of AVXL's -104633.80%. Michael Burry suspects a big gap in pre-sales traction.
-6.76%
Less than half of AVXL's -99.03%. David Dodd sees fewer expansions in other current obligations.
-9.79%
Less than half of AVXL's 3.54%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Less than half of AVXL's 3.54%. David Dodd sees far fewer liability expansions relative to competitor.
0.31%
Higher Common Stock (Book Value) Growth compared to AVXL's zero value, indicating worse performance.
-2.40%
≥ 1.5x AVXL's -0.40%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-68.44%
≥ 1.5x AVXL's -3.45%. David Dodd sees stronger capital base growth than competitor.
-29.38%
Below half AVXL's 614.58%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AVXL's -0.48%. Michael Burry sees a major jump. Investigate leverage rationale.
28.92%
Less than half of AVXL's -0.64%. David Dodd sees better deleveraging or stronger cash buildup than competitor.